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Background: The number of potential regimens of drug treat-
ment for TB is vast, meaning that evaluating each new treatment
against a control in separate two-arm trials requires a huge amount
of resources. There is, therefore, a need for innovative trial designs
that can evaluate drug regimens simultaneously.
Methods & Materials: TRUNCATE-TB (two-month regimens
using novel combinations to augment treatment effectiveness for
drug-sensitive tuberculosis) is a randomised, open-label, multi-
arm, multi-stage (MAMS), parallel group strategy trial. The MAMS
design has been applied successfuly in a trial of multiple regi-
mens for prostate cancer, and more recently in a TB trial. In the
MAMS design, the trial starts with multiple arms, and, as it pro-
gresses, recruitment to those arms that do not show sufﬁcient
promise on an early interim outcome measure are discontinued,
whilst recruitment to the control arm and remaining promising
novel boosted arms continues until sufﬁcient numbers of patients
have been enrolled to assess the outcome on the deﬁned primary
outcome. Recommendations about stoppingor continuing armsare
made by an Independent Data Monitoring Committee on the basis
of safety and efﬁcacy data.
Results: Up to 1080 adult patients with pulmonary TB (diag-
nosed using sputum GeneXpert) will be randomised at equal
probability to receive 6-months standard treatment as a control, or
to one of a number of boosted regimens (these regimens are combi-
nations of standard drugswith new or repurposed drugs including:
high-dose rifampicin, linezolid, clofazimine, bedaquiline, dela-
manid, rifapentine or levoﬂoxacin.
Conclusion: The primary aim of the trial is to determine
whether a strategy of treating drug-sensitive TB for 2 months
with one of a number of novel combination regimens and re-
treating relapse with a 6-month course of standard treatment
will be non-inferior to the standard WHO-recommended 6-month
treatment/8-month re-treatment approach in terms of TB sputum
culture status at 2 years after randomisation. The secondary aims
are to assess the possible advantages of the TRUNCATE-TB man-
agement strategy compared to the standard management strategy
from the patient perspective (including acceptability, quality of
life and clinical adverse events) and the programme perspective
(including treatment adherence, default, new drug resistance and
community transmission) as well as cost-effectiveness.
http://dx.doi.org/10.1016/j.ijid.2016.02.863
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Background: Tuberculosis (TB) continues to be one of the
main causes of morbidity and mortality worldwide. The alarming
increase in the rate of HIV-related TB, pediatric TB, latent TB, Multi
DrugResistant (MDR)andExtensivelyDrugResistant (XDR)TBpose
serious problem around the world. The treatment for tuberculosis
requires very long duration with combination of antibiotics (6-8
months for new cases and 18-24 months for MDR TB). Two mech-
anisms are thought to be involved in the natural drug resistance
of mycobacteria: the mycobacterial cell wall permeability barrier
and active multidrug efﬂux pumps. Genes encoding drug efﬂux
transportershavebeen isolated fromseveralmycobacterial species.
These proteins transport tetracycline, ﬂuoroquinolones, aminogly-
cosides and other compounds. Recent reports have suggested that
efﬂux pumps may also be involved in transporting isoniazid, one of
themain drugs used to treat tuberculosis. Inmost bacterial species,
efﬂux pump inhibitors (EPI) can reduce resistance levels both in
wild-type strains and in those with acquired target mutations.
Methods & Materials: Identiﬁcation of MTB efﬂux pump genes
MDR-MTB identiﬁcation
Gene Cloning from MDR-MTB, Nucleotide sequencing and
Mutation analysis
Isolation and indetiﬁcation of Peptide inhibitors fromLactic acid
bacteria (LAB)
Mycobacterium tuberculosis inhibitor assay
Luciferase assay
Results: In this study we have identiﬁed a list of genes which
might function as potential drug efﬂux pumps from the MDR-MTB
clinical isolates. These genes were identiﬁed based on sequence
analysis of the corresponding efﬂux genes with that of the MTB
strain H37Rv. Crucial mutations in these genes might have an
important role in the drug efﬂux inMDR-MTB. The identiﬁed genes
were expressed in drug resistant E.coli. The isolated peptides from
LAB and known drug efﬂux pump inhibitors in combination with
RIF and INH were tested in E.coli (Efﬂux genes) and MDR-MTB.
Conclusion: Nucleotide comparison studies with the H37Rv
strain we have identiﬁed potential candidate genes related to drug
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efﬂux inMDR-MTB strains. Novel peptide inhibitors identiﬁed from
Lactic Acid Bacteria shows high inhibition against the MDR-MTB.
Thesepeptideshas thepotential to bedevelopedas efﬂux inhibitors
against MDR MTB.
http://dx.doi.org/10.1016/j.ijid.2016.02.864
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Background: Multidrug resistant tuberculosis (MDR-TB) is of
growing health concern globally and in India. MDR-TB is deﬁned as
Mycobacterium tuberculosis resistant to Isoniazid and Rifampicin.
The current prevalence of MDR-TB in India is 2.3% (ranging
from1.8%-2.8%)and17.2% (ranging from14.9%-19.5%) amongnewly
diagnosedandpreviously treatedcases respectively. Increasedcost,
more side effects and longer duration of treatment makes MDR-TB
management a great challenge.
Methods & Materials: The present study was conducted as
an Unmatched Case Control study to identify the determinants of
MDR-TB. The study was conducted in all the 14 Tuberculosis units
(TU) of Revised National Tuberculosis Control Programme (RNTCP)
under the Municipal Corporation of Bengaluru. The source of the
study subjects were patients registered under 14 TUs during the
period of January 2013 to June 2014, with 52 MDR-TB patients as
Cases and 53 non MDR-TB patients as Controls. Cases and controls
were conﬁrmed by culture and drug susceptibility test done at the
Intermediate Reference Laboratory (IRL), Bengaluru. Both cases and
controlswere interviewed at their residence using a pretested semi
structured questionnaire.
Results: Univariate analysis including descriptive statistics
along with Chi-square test and multivariate logistic regression
were used to analyse the data. The mean age of the cases was
38.5±15.8 years which was almost similar to that of the controls
(38.5±13.0 years). Univariate analysis revealed - the number of
previous episodes of TB, type of health setup approached during
the ﬁrst episode of TB, treatment outcome of the ﬁrst episode of
TB, Gender, employment status, religion, education and socioeco-
nomic status as statistically signiﬁcant determinants of MDR-TB.
After adjusting for potential confounders with multivariate logis-
tic regression – the number of previous episodes of TB (OR=4.08,
95%CI: 1.53-10.86), the treatment outcome of the ﬁrst episode of
TB(OR=2.15, 95%CI: 1.42-3.25) and gender (OR=3.14, 95%CI: 1.18-
8.29) were found to be independent determinants of MDR-TB.
Conclusion: Hence prompt treatment of newly diagnosed cases
of tuberculosis in the ﬁrst instance is critical in prevention of MDR-
TB. Adequate counselling regarding treatment adherence to the
patients at theﬁrst episodeof TBwill ensure compliance and reduce
the chances of drug resistance.
http://dx.doi.org/10.1016/j.ijid.2016.02.865
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Mycobacterial dormancy associated proteins:
Role in the survival of bacteria under stress
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Background: Mycobacterium tuberculosis, the cause of tuber-
culosis in humans, is present approximately in one third of
the world’s population, mostly in a dormant state. The proteins
encoded by the dormancy survival regulon (DosR regulon) are
mainly responsible for survival of the bacilli in a latent form. To
maintain latency, mycobacteria orchestrate a balanced interplay of
different cytokines secreted by immune cells during the granulo-
matous stage. The function of most of the DosR regulon proteins
of M. tuberculosis is unknown. Rv3131 and Rv2004c are members
of DoSR antigens category and conserved hypothetical proteins
which are signiﬁcantly up-regulated under different stress condi-
tions. Rv3131 contains FMN binding nitroreductase domain and is
predicted to be responsible for virulence, detoxiﬁcation and adap-
tation of bacteria under hostile conditions. Rv2004c was reported
to be localized on the surface of M.tb and its high active bind-
ing peptide sequence interacts with U937 macrophages and A549
epithelial cells.
Methods & Materials: Rv3131 and Rv2004c genes were cloned
and respective proteins were puriﬁed.
Results: In this study, we have shown that the DosR regulon
proteins, encoded by the genes Rv3131 and Rv2004c, can stimu-
late macrophages and peripheral blood mononuclear cells (PBMC)
to secrete important cytokines thatmaybe signiﬁcant ingranuloma
formation and its maintenance. Computational modeling, docking
and simulation study suggested that these proteins might interact
with TLR2. This was further conﬁrmed through the interaction of
recombinant Rv3131 and 2004c with TLR2 expressed by HEK293
cells. In THP-1 cells treated with RV3131 and 2004c, Tlr2 mRNA
levels were signiﬁcantly increased. When in vitro differentiated
THP-1 cells were treated with recombinant Rv3131 and Rv2004c,
increased secretion of TNF- , IL-1b and IL-8 was observed in a
dose dependent manner. Similarly, human PBMCs when treated
with recombinant Rv3131 and 2004c, showed upregulated secre-
tion of pro-inﬂammatory cytokines IFN-ɼ, TNF-, IL-1b and IL-8.
FACS analyses on THP-1 cell surface followingRV3131 andRv2004c
protein treatment demonstrated increased expression of TLR2. Fur-
ther experiments are being carried out to decipher the functional
role of these proteins.
Conclusion: The cytokine proﬁles dissected herein point to a
possible role of these proteins in maintenance of latency with the
help of the pro-inﬂammatory responses.
http://dx.doi.org/10.1016/j.ijid.2016.02.866
